Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7926944 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL17923466 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL9431529 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL19287109 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL11575727 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL179941 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL2094913 | 1.00 | — | — | |
| SCHEMBL11251398 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL994389 | 0.97 | — | — | |
| SCHEMBL481638 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115806503-B | Selective histone deacetylase inhibitor and preparation method and application thereof | 中国海洋大学 | 2025-03-07 | — | — | CN | disclosed |
| US-9943532-B2 | Iminosugars and methods of treating viral diseases | EMERGENT VIROLOGY LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170304333-A1 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES | EMERGENT VIROLOGY LLC (US) | 2017-10-26 | — | — | US | disclosed |
| EP-2320886-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9579334-B2 | Iminosugars and methods of treating viral diseases | EMERGENT VIROLOGY LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160243096-A1 | METHODS OF TREATING ORTHOMYXOVIRAL INFECTIONS | EMERGENT VIROLOGY LLC (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160243097-A1 | METHODS OF TREATING POXVIRAL INFECTIONS | EMERGENT VIROLOGY LLC (US) | 2016-08-25 | — | — | US | disclosed |
| EP-2398321-B1 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES | UNITED THERAPEUTICS CORP (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2400843-B1 | IMINOSUGARS AND METHODS OF TREATING ARENAVIRAL INFECTIONS | UNITED THERAPEUTICS CORP (US) | 2015-11-11 | — | — | EP | disclosed |
| US-20150224128-A1 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES | UNITED THERAPEUTICS CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-20110065752-A1 | METHODS OF TREATING ORTHOMYXOVIRAL INFECTIONS | UNITED THERAPEUTICS CORPORATION | 2011-03-17 | — | — | US | disclosed |
| WO-2011028781-A1 | METHODS OF TREATING POXVIRAL INFECTIONS | UNITED THERAPEUTICS CORPORATION (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028779-A1 | IMINOSUGARS AND METHODS OF TREATING FILOVIRAL DISEASES | UNITED THERAPEUTICS CORPORATION (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028775-A1 | METHODS OF TREATING ORTHOMYXOVIRAL INFECTIONS | UNITED THERAPEUTICS CORPORATION (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20100317696-A1 | IMINOSUGARS AND METHODS OF TREATING BUNYAVIRAL AND TOGAVIRAL DISEASES | UNITED THERAPEUTICS CORPORATION | 2010-12-16 | — | — | US | disclosed |
| WO-2010144759-A1 | IMINOSUGARS AND METHODS OF TREATING BUNYAVIRAL AND TOGAVIRAL DISEASES | UNITED THERAPEUTICS CORPORATION (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010099064-A1 | IMINOSUGARS AND METHODS OF TREATING ARENAVIRAL INFECTIONS | UNITED THERAPEUTICS CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100222383-A1 | Iminosugars and methods of treating viral diseases | UNITED THERAPEUTICS CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222384-A1 | Iminosugars and methods of treating arenaviral infections | UNITED THERAPEUTICS CORPORATION | 2010-09-02 | — | — | US | disclosed |
| WO-2010096764-A1 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES | UNITED THERAPEUTICS CORPORATION (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222383-A1 | Iminosugars and methods of treating viral diseases | GBA1, UGCG, HAVCR2 | TSHR 3979/4885FAAH 720/4885TRPV1 4350/4885 |
| US-20160243096-A1 | METHODS OF TREATING ORTHOMYXOVIRAL INFECTIONS | EIF2AK2, ENGASE, MANBA | TSHR 4202/4885FAAH 2070/4885TRPV1 4026/4885 |
| US-20100222384-A1 | Iminosugars and methods of treating arenaviral infections | EIF2AK2, UGCG, ASAH2 | TSHR 4598/4885FAAH 1360/4885TRPV1 2475/4885 |
| US-20160243097-A1 | METHODS OF TREATING POXVIRAL INFECTIONS | DPM1, EIF2AK2, DERA | TSHR 4639/4885FAAH 2753/4885TRPV1 3659/4885 |
| US-20150224128-A1 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES | GBA1, UGCG, HAVCR2 | TSHR 3979/4885FAAH 720/4885TRPV1 4350/4885 |
| US-20110065752-A1 | METHODS OF TREATING ORTHOMYXOVIRAL INFECTIONS | EIF2AK2, ENGASE, MANBA | TSHR 4202/4885FAAH 2070/4885TRPV1 4026/4885 |
| US-20100317696-A1 | IMINOSUGARS AND METHODS OF TREATING BUNYAVIRAL AND TOGAVIRAL DISEASES | EIF2AK2, ENGASE, IPO9 | TSHR 4121/4885FAAH 2663/4885TRPV1 4360/4885 |
| US-20170304333-A1 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES | GBA1, UGCG, HAVCR2 | TSHR 3979/4885FAAH 720/4885TRPV1 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.